[go: up one dir, main page]

WO2008154350A3 - Utilisation d'agonistes de jonctions serrées pour supprimer des réponses immunes - Google Patents

Utilisation d'agonistes de jonctions serrées pour supprimer des réponses immunes Download PDF

Info

Publication number
WO2008154350A3
WO2008154350A3 PCT/US2008/066057 US2008066057W WO2008154350A3 WO 2008154350 A3 WO2008154350 A3 WO 2008154350A3 US 2008066057 W US2008066057 W US 2008066057W WO 2008154350 A3 WO2008154350 A3 WO 2008154350A3
Authority
WO
WIPO (PCT)
Prior art keywords
tight junction
immune responses
suppress immune
agonists
junction agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/066057
Other languages
English (en)
Other versions
WO2008154350A2 (fr
Inventor
Amir Tamiz
Niranjan Pandey
Blake Paterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
9 Meters Biopharma Inc
Original Assignee
Alba Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alba Therapeutics Corp filed Critical Alba Therapeutics Corp
Publication of WO2008154350A2 publication Critical patent/WO2008154350A2/fr
Publication of WO2008154350A3 publication Critical patent/WO2008154350A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des susbtances et des procédés permettant de supprimer une réponse immune excessive ou non désirée. Selon certains modes de mise en oeuvre, des agonistes des voies biologiques responsables de l'ouverture et de la fermeture des jonctions serrées (par exemple, des agonistes de jonctions serrées) sont utilisés dans des compositions présentant des antigènes afin de supprimer une réponse immune contre l'antigène.
PCT/US2008/066057 2007-06-08 2008-06-06 Utilisation d'agonistes de jonctions serrées pour supprimer des réponses immunes Ceased WO2008154350A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94297807P 2007-06-08 2007-06-08
US60/942,978 2007-06-08

Publications (2)

Publication Number Publication Date
WO2008154350A2 WO2008154350A2 (fr) 2008-12-18
WO2008154350A3 true WO2008154350A3 (fr) 2009-02-26

Family

ID=40130444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/066057 Ceased WO2008154350A2 (fr) 2007-06-08 2008-06-06 Utilisation d'agonistes de jonctions serrées pour supprimer des réponses immunes

Country Status (1)

Country Link
WO (1) WO2008154350A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338297A (en) * 1980-02-19 1982-07-06 Michael Jacob G Polypeptide active pollen immunosuppressant fraction
US20050119171A1 (en) * 2001-08-10 2005-06-02 Genset S.A. Human cdnas and proteins and uses thereof
US20060165722A1 (en) * 2005-01-14 2006-07-27 University Of Maryland, Baltimore Peptides for delivery of mucosal vaccines
US20060276399A1 (en) * 1998-08-03 2006-12-07 University Of Maryland - Baltimore Peptide antagonists of zonulin and methods for use of the same
US20070122423A1 (en) * 2001-08-17 2007-05-31 Glaxosmithkline Biologicals Sa Derp1 and proderp1 allergen derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338297A (en) * 1980-02-19 1982-07-06 Michael Jacob G Polypeptide active pollen immunosuppressant fraction
US20060276399A1 (en) * 1998-08-03 2006-12-07 University Of Maryland - Baltimore Peptide antagonists of zonulin and methods for use of the same
US20050119171A1 (en) * 2001-08-10 2005-06-02 Genset S.A. Human cdnas and proteins and uses thereof
US20070122423A1 (en) * 2001-08-17 2007-05-31 Glaxosmithkline Biologicals Sa Derp1 and proderp1 allergen derivatives
US20060165722A1 (en) * 2005-01-14 2006-07-27 University Of Maryland, Baltimore Peptides for delivery of mucosal vaccines

Also Published As

Publication number Publication date
WO2008154350A2 (fr) 2008-12-18

Similar Documents

Publication Publication Date Title
WO2007100908A3 (fr) Vecteurs anédoviraux chimériques
LTC1971366I2 (lt) Žmogaus anti-IL-23 antikūnai, kompozicijos, metodai ir panaudojimai
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
WO2010011944A3 (fr) Procédés de criblage de protéines
WO2007084321A3 (fr) Anticorps dirigés contre ox-2/cd200 et utilisations correspondantes
PH12019501796A1 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
WO2011047087A3 (fr) Détection de protéine par l'intermédiaire de nanorapporteurs
NO20084356L (no) Anti TAT226-antistoffer og immunokonjugater
WO2017147542A3 (fr) Conjugaison optimisée d'anticorps spécifique d'un site de transglutaminase
MX2009013199A (es) Anticuerpos anti-notch1 nnr y sus metodos de uso.
IL204542A (en) Unique monoclonal antibodies for protofibrillary form of cellulose-amyloid protein, methods and uses thereof
CU20120095A7 (es) Antagonistas de pcsk9
WO2007133290A3 (fr) Anticorps anti-ox40l et méthodes correspondantes
BRPI0812488A2 (pt) Anticorpos anti-cd44 humanizados e quiméricos que mediam citotoxidade de célula de câncer, usos dos mesmos, ensaios de ligação, métodos, composições e kit de ensaio
WO2006083936A3 (fr) Anticorps anti-ephb2 et methodes d'utilisation associees
BRPI0821211A2 (pt) Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.
EP4219560A3 (fr) Anticorps neutralisant l'intégrine alpha v bêta 8
WO2009134429A3 (fr) Procédés et compositions pour moduler une tolérance immunologique
WO2011053565A3 (fr) Compositions et méthodes de détection d'une tauopathie
WO2009035738A3 (fr) Utilisation d'une analyse elispot de cellules sécrétrices d'anticorps pour évaluer les réponses des anticorps suite à leur exposition à un antigène
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
WO2015009740A3 (fr) Agents de liaison anti-mucine 1 et leurs utilisations
WO2008043000A3 (fr) Différenciation entre animaux vaccinés et animaux infectés (differentiate infected from vaccinated animals : diva) par ehrlicia canis
WO2009070507A3 (fr) Antigènes d'anaplasma phagocytophilum (aph) et anticorps spécifiques des anaplasmes
WO2010009856A3 (fr) Protéine de liaison d’antigène goodpasture et sa détection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08770290

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08770290

Country of ref document: EP

Kind code of ref document: A2